PREDNISONE INTENSOL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Prednisone Intensol, and when can generic versions of Prednisone Intensol launch?
Prednisone Intensol is a drug marketed by Hikma and is included in one NDA.
The generic ingredient in PREDNISONE INTENSOL is prednisone. There are sixteen drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the prednisone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Prednisone Intensol
A generic version of PREDNISONE INTENSOL was approved as prednisone by WATSON LABS on December 31st, 1969.
Summary for PREDNISONE INTENSOL
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 89 |
Clinical Trials: | 70 |
Patent Applications: | 6,235 |
Formulation / Manufacturing: | see details |
DailyMed Link: | PREDNISONE INTENSOL at DailyMed |
Recent Clinical Trials for PREDNISONE INTENSOL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Children's Oncology Group | Phase 2 |
Mayo Clinic | Phase 2 |
Joseph Tuscano | Phase 2 |
Pharmacology for PREDNISONE INTENSOL
Drug Class | Corticosteroid |
Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for PREDNISONE INTENSOL
US Patents and Regulatory Information for PREDNISONE INTENSOL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hikma | PREDNISONE INTENSOL | prednisone | SOLUTION;ORAL | 088810-001 | Feb 20, 1985 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |